Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Palbociclib

FDA-approved product (capsule, oral), marketed as Ibrance, Palbociclib.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Palbociclib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Cyclin-dependent kinase (cdk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Palbociclib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Palbociclib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

    NCT01864746 · start 2013-10-30

    Registered record
    Registry ID
    NCT01864746
    Conditions
    Breast Cancer; Hormonreceptor Positive; Her2-normal; Postneoadjuvant Treatment With CDK 4/6 Inhibitor; CPS-EG Score
    Interventions
    Palbociclib PD-0332991; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-10-30
    Completion
    2020-12-21
    Enrolment
    1,250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Hormonreceptor Positive; Her2-normal; Postneoadjuvant Treatment With CDK 4/6 Inhibitor +1 more
    InterventionPalbociclib PD-0332991; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

    NCT01942135 · start 2013-09-26

    Registered record
    Registry ID
    NCT01942135
    Conditions
    Metastatic Breast Cancer
    Interventions
    Palbociclib; Fulvestrant; Placebo; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-26
    Completion
    2022-09-28
    Enrolment
    521

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionPalbociclib; Fulvestrant; Placebo; Fulvestrant
    PhasePhase 3
    Registry statusCompleted

  • A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.

    NCT01756781 · start 2013-05

    Registered record
    Registry ID
    NCT01756781
    Conditions
    Healthy
    Interventions
    Midazolam; PD-0332991; Midazolam; PD-0332991
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-05
    Completion
    2013-07
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMidazolam; PD-0332991; Midazolam; PD-0332991
    PhasePhase 1
    Registry statusCompleted

  • PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

    NCT01723774 · start 2013-04-10

    Registered record
    Registry ID
    NCT01723774
    Conditions
    Breast Neoplasms
    Interventions
    PD0332991; Anastrozole; Goserelin; Surgery (standard of care); Tumor biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2013-04-10
    Completion
    2026-08-24
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionPD0332991; Anastrozole; Goserelin; Surgery (standard of care) +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

    NCT01740427 · start 2013-02-22

    Registered record
    Registry ID
    NCT01740427
    Conditions
    Breast Neoplasms
    Interventions
    PD-0332991; Letrozole; Placebo; Letrozole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-02-22
    Completion
    2023-11-09
    Enrolment
    666

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionPD-0332991; Letrozole; Placebo; Letrozole
    PhasePhase 3
    Registry statusCompleted